Charles River Laboratories International (CRL) 10-Q 2 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 24, 2022	Oct. 21, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 24, 2022
Document Transition Report	false
Entity File Number	001-15943
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1397316
Entity Address, Address Line One	251 Ballardvale Street
Entity Address, City or Town	Wilmington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01887
City Area Code	781
Local Phone Number	222-6000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	CRL
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,878,656
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Total revenue	$ 989,157	$ 895,937	$ 2,876,217	$ 2,635,110
Costs and expenses:
Selling, general and administrative	183,714	148,573	465,458	475,807
Amortization of intangible assets	35,533	32,852	111,144	94,664
Operating income	150,976	155,802	487,165	417,055
Other income (expense):
Interest income	122	137	437	343
Interest expense	(11,375)	(16,455)	(24,512)	(62,364)
Other expense, net	(16,616)	(16,214)	(85,024)	(37,966)
Income before income taxes	123,107	123,270	378,066	317,068
Provision for income taxes	25,495	18,111	74,564	58,058
Net income	97,612	105,159	303,502	259,010
Less: Net income attributable to noncontrolling interests	1,139	1,733	4,686	5,606
Net income attributable to common shareholders	$ 96,473	$ 103,426	$ 298,816	$ 253,404
Earnings per common share
Basic (in dollars per share)	$ 1.90	$ 2.05	$ 5.88	$ 5.04
Diluted (in dollars per share)	$ 1.88	$ 2.01	$ 5.83	$ 4.93
Weighted-average number of common shares outstanding:
Basic (in shares)	50,870	50,425	50,778	50,234
Diluted (in shares)	51,283	51,558	51,285	51,360
Service
Total revenue	$ 812,894	$ 703,859	$ 2,316,206	$ 2,045,760
Costs and expenses:
Cost of services provided and products sold (excluding amortization of intangible assets)	530,706	468,659	1,540,193	1,369,396
Product
Total revenue	176,263	192,078	560,011	589,350
Costs and expenses:
Cost of services provided and products sold (excluding amortization of intangible assets)	$ 88,228	$ 90,051	$ 272,257	$ 278,188

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 97,612	$ 105,159	$ 303,502	$ 259,010
Other comprehensive income (loss):
Foreign currency translation adjustment	(151,294)	(28,909)	(258,103)	1,747
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans	731	991	2,218	2,972
Comprehensive (loss) income, before income taxes related to items of other comprehensive income	(52,951)	77,241	47,617	263,729
Less: Income tax benefit related to items of other comprehensive income	(11,201)	(3,140)	(20,095)	(1,716)
Comprehensive (loss) income, net of income taxes	(41,750)	80,381	67,712	265,445
Less: Comprehensive (loss) income related to noncontrolling interests, net of income taxes	(1,170)	1,713	(236)	5,946
Comprehensive (loss) income attributable to common shareholders, net of income taxes	$ (40,580)	$ 78,668	$ 67,948	$ 259,499

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
Current assets:
Cash and cash equivalents	$ 193,701	$ 241,214
Trade receivables and contract assets, net of allowances for credit losses of $9,827 and $7,180, respectively	770,776	642,881
Inventories	261,522	199,146
Prepaid assets	92,266	93,543
Other current assets	97,087	97,311
Total current assets	1,415,352	1,274,095
Property, plant and equipment, net	1,380,568	1,291,068
Operating lease right-of-use assets, net	373,410	292,941
Goodwill	2,776,005	2,711,881
Client relationships and other intangible assets, net	968,020	1,061,192
Deferred tax assets	39,721	40,226
Other assets	429,693	352,889
Total assets	7,382,769	7,024,292
Current liabilities:
Current portion of long-term debt and finance leases	2,079	2,795
Accounts payable	181,629	198,130
Accrued compensation	200,365	246,119
Deferred revenue	251,473	219,703
Accrued liabilities	196,754	228,797
Other current liabilities	181,894	137,641
Total current liabilities	1,014,194	1,033,185
Long-term debt, net and finance leases	2,937,056	2,663,564
Operating lease right-of-use liabilities	368,851	252,972
Deferred tax liabilities	196,014	239,720
Other long-term liabilities	194,710	242,859
Total liabilities	4,710,825	4,432,300
Commitments and contingencies (Notes 2, 9, 11 and 13)
Redeemable noncontrolling interests	39,206	53,010
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 51,006 shares issued and 50,877 shares outstanding as of September 24, 2022, and 50,480 shares issued and outstanding as of December 25, 2021	510	505
Additional paid-in capital	1,780,876	1,718,304
Retained earnings	1,279,567	980,751
Treasury stock, at cost, 129 and 0 shares, as of September 24, 2022 and December 25, 2021, respectively	(38,492)	0
Accumulated other comprehensive loss	(395,608)	(164,740)
Total equity attributable to common shareholders	2,626,853	2,534,820
Noncontrolling interest	5,885	4,162
Total equity	2,632,738	2,538,982
Total liabilities, redeemable noncontrolling interests and equity	7,382,769	7,024,292
Client relationships, net
Current assets:
Client relationships and other intangible assets, net	909,899	981,398
Other intangible assets, net
Current assets:
Client relationships and other intangible assets, net	$ 58,121	$ 79,794

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 9,827	$ 7,180
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	51,006,000	50,480,000
Common stock, shares outstanding (in shares)	50,877,000	50,480,000
Treasury stock, shares (in shares)	129,000	0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021
Cash flows relating to operating activities
Net income	$ 303,502	$ 259,010
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	226,325	198,299
Stock-based compensation	51,548	52,289
Loss on debt extinguishment and amortization of other financing costs	3,054	28,972
Deferred income taxes	(26,323)	(13,757)
Loss on venture capital and strategic equity investments, net	20,068	17,277
Contingent consideration, fair value changes	(15,420)	(10,360)
Other, net	31,574	928
Changes in assets and liabilities:
Trade receivables and contract assets, net	(174,169)	(35,592)
Inventories	(76,283)	(5,639)
Accounts payable	5,979	11,431
Accrued compensation	(32,734)	18,210
Deferred revenue	53,565	(9,394)
Customer contract deposits	16,234	4,850
Other assets and liabilities, net	(2,037)	15,017
Net cash provided by operating activities	384,883	531,541
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(283,392)	(1,292,093)
Capital expenditures	(235,709)	(129,997)
Purchases of investments and contributions to venture capital investments	(129,363)	(31,963)
Proceeds from sale of investments	3,104	5,960
Other, net	(6,945)	854
Net cash used in investing activities	(652,305)	(1,447,239)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	2,798,665	6,119,671
Proceeds from exercises of stock options	17,710	43,314
Payments on long-term debt, revolving credit facility, and finance lease obligations	(2,524,387)	(5,190,394)
Purchase of treasury stock	(38,492)	(40,440)
Payment of debt extinguishment and financing costs	0	(38,253)
Purchases of additional equity interests, net	(30,533)	0
Payment of contingent considerations	(10,356)	(2,328)
Other, net	(6,048)	0
Net cash provided by financing activities	206,559	891,570
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	10,726	17,514
Net change in cash, cash equivalents, and restricted cash	(50,137)	(6,614)
Cash, cash equivalents, and restricted cash, beginning of period	246,314	233,119
Cash, cash equivalents, and restricted cash, end of period	196,177	226,505
Supplemental cash flow information:
Cash and cash equivalents	193,701	212,539
Cash classified within current assets held for sale	0	8,612
Restricted cash included in Other current assets	1,376	4,275
Restricted cash included in Other assets	1,100	1,079
Cash, cash equivalents, and restricted cash, end of period	$ 196,177	$ 226,505

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total Equity Attributable to Common Shareholders	Noncontrolling Interest
Beginning balance (in shares) at Dec. 26, 2020		49,767
Beginning balance (in shares) at Dec. 26, 2020						0
Beginning balance at Dec. 26, 2020	$ 2,118,169	$ 498	$ 1,627,564	$ 625,414	$ (138,874)	$ 0	$ 2,114,602	$ 3,567
Increase (Decrease) in Stockholders' Equity
Net income	62,220			61,530			61,530	690
Other comprehensive income (loss)	11,857				11,857		11,857
Adjustment of redeemable noncontrolling interest to redemption value	(835)		(835)				(835)
Issuance of stock under employee compensation plans (in shares)		583
Issuance of stock under employee compensation plans	19,612	$ 6	19,606				19,612
Purchase of treasury shares (in shares)						134
Purchase of treasury shares	(36,028)					$ (36,028)	(36,028)
Stock-based compensation	13,189		13,189				13,189
Ending balance (in shares) at Mar. 27, 2021		50,350
Ending balance (in shares) at Mar. 27, 2021						134
Ending balance at Mar. 27, 2021	2,188,184	$ 504	1,659,524	686,944	(127,017)	$ (36,028)	2,183,927	4,257
Increase (Decrease) in Stockholders' Equity
Net income	89,031			88,448			88,448	583
Other comprehensive income (loss)	18,996				18,996		18,996
Adjustment of redeemable noncontrolling interest to redemption value	(1,506)		(1,506)				(1,506)
Issuance of stock under employee compensation plans (in shares)		188
Issuance of stock under employee compensation plans	15,767	$ 1	15,766				15,767
Purchase of treasury shares (in shares)						13
Purchase of treasury shares	(4,269)					$ (4,269)	(4,269)
Stock-based compensation	17,077		17,077				17,077
Ending balance (in shares) at Jun. 26, 2021		50,538
Ending balance (in shares) at Jun. 26, 2021						147
Ending balance at Jun. 26, 2021	2,323,280	$ 505	1,690,861	775,392	(108,021)	$ (40,297)	2,318,440	4,840
Increase (Decrease) in Stockholders' Equity
Net income	104,085			103,426			103,426	659
Other comprehensive income (loss)	(24,758)				(24,758)		(24,758)
Adjustment of redeemable noncontrolling interest to redemption value	(702)		(702)				(702)
Issuance of stock under employee compensation plans (in shares)		69
Issuance of stock under employee compensation plans	8,280	$ 1	8,279				8,280
Purchase of treasury shares (in shares)						0
Purchase of treasury shares	(143)					$ (143)	(143)
Stock-based compensation	22,023		22,023				22,023
Ending balance (in shares) at Sep. 25, 2021		50,607
Ending balance (in shares) at Sep. 25, 2021						147
Ending balance at Sep. 25, 2021	$ 2,432,065	$ 506	1,720,461	878,818	(132,779)	$ (40,440)	2,426,566	5,499
Beginning balance (in shares) at Dec. 25, 2021	50,480	50,480
Beginning balance (in shares) at Dec. 25, 2021	0					0
Beginning balance at Dec. 25, 2021	$ 2,538,982	$ 505	1,718,304	980,751	(164,740)	$ 0	2,534,820	4,162
Increase (Decrease) in Stockholders' Equity
Net income	93,582			93,022			93,022	560
Other comprehensive income (loss)	(10,193)				(10,193)		(10,193)
Adjustment of redeemable noncontrolling interest to redemption value	(1,161)		(1,161)				(1,161)
Issuance of stock under employee compensation plans (in shares)		431
Issuance of stock under employee compensation plans	13,071	$ 4	13,067				13,071
Purchase of treasury shares (in shares)						111
Purchase of treasury shares	(33,994)					$ (33,994)	(33,994)
Stock-based compensation	14,619		14,619				14,619
Ending balance (in shares) at Mar. 26, 2022		50,911
Ending balance (in shares) at Mar. 26, 2022						111
Ending balance at Mar. 26, 2022	2,614,906	$ 509	1,744,829	1,073,773	(174,933)	$ (33,994)	2,610,184	4,722
Increase (Decrease) in Stockholders' Equity
Net income	109,820			109,321			109,321	499
Other comprehensive income (loss)	(83,622)				(83,622)		(83,622)
Adjustment of redeemable noncontrolling interest to redemption value	(1,132)		(1,132)				(1,132)
Issuance of stock under employee compensation plans (in shares)		79
Issuance of stock under employee compensation plans	2,499	$ 1	2,498				2,499
Purchase of treasury shares (in shares)						18
Purchase of treasury shares	(4,474)					$ (4,474)	(4,474)
Stock-based compensation	14,930		14,930				14,930
Ending balance (in shares) at Jun. 25, 2022		50,990
Ending balance (in shares) at Jun. 25, 2022						129
Ending balance at Jun. 25, 2022	2,652,927	$ 510	1,761,125	1,183,094	(258,555)	$ (38,468)	2,647,706	5,221
Increase (Decrease) in Stockholders' Equity
Net income	97,137			96,473			96,473	664
Other comprehensive income (loss)	(137,053)				(137,053)		(137,053)
Adjustment of redeemable noncontrolling interest to redemption value	(4,388)		(4,388)				(4,388)
Issuance of stock under employee compensation plans (in shares)		16
Issuance of stock under employee compensation plans	2,140		2,140				2,140
Purchase of treasury shares	(24)					$ (24)	(24)
Stock-based compensation	$ 21,999		21,999				21,999
Ending balance (in shares) at Sep. 24, 2022	50,877	51,006
Ending balance (in shares) at Sep. 24, 2022	129					129
Ending balance at Sep. 24, 2022	$ 2,632,738	$ 510	$ 1,780,876	$ 1,279,567	$ (395,608)	$ (38,492)	$ 2,626,853	$ 5,885

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 24, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2021. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Newly Issued Accounting Pronouncements In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” ASU 2022-04 requires quantitative and qualitative disclosures about the use of supplier finance programs. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for selected disclosures, and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures of the consolidated financial statements, but does not believe there will be a material impact. In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.” ASU 2022-03 sets disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU also clarifies that contractual sale restrictions should not be considered when measuring fair value of equity securities. The ASU is effective for fiscal years beginning after December 15, 2023 and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures, but does not believe there will be a material impact. In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities About Government Assistance.” ASU 2021-10 requires disclosures about transactions with a government that have been accounted for by a grant or contribution accounting model to increase transparency about the types of transactions, the accounting for the transactions, and the effect on the financial statements. The ASU is an annual disclosure effective for fiscal years beginning after December 15, 2021 and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures, but does not believe there will be a material impact. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2021. Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which will occur in this fiscal year 2022. Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research and GMP-Compliant Cells businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services); and Research and GMP-Compliant Cells, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and nonregulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO); Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens.

ACQUISITIONS AND DIVESTITURES

ACQUISITIONS AND DIVESTITURES	9 Months Ended
	Sep. 24, 2022
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS AND DIVESTITURES	ACQUISITIONS AND DIVESTITURES Fiscal 2022 Acquisition Explora BioLabs Holdings, Inc. On April 5, 2022, the Company acquired Explora BioLabs Holdings, Inc. (Explora BioLabs), a provider of contract vivarium research services, providing biopharmaceutical clients with turnkey in vivo vivarium facilities, management and related services to efficiently conduct their early-stage research activities. The acquisition of Explora BioLabs complements the Company’s existing Insourcing Solutions business, specifically the CRADL (Charles River Accelerator and Development Lab) footprint, and offers incremental opportunities to partner with an emerging client base, many of which are engaged in cell and gene therapy development. The purchase price of Explora BioLabs was $284.5 million, net of $6.6 million in cash. The acquisition was funded through proceeds from the Company’s credit facility (Credit Facility). This business is reported as part of the Company’s RMS reportable segment. Fiscal 2021 Acquisitions Vigene Biosciences, Inc. On June 28, 2021, the Company acquired Vigene Biosciences, Inc. (Vigene), a gene therapy CDMO, providing viral vector-based gene delivery solutions. The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The purchase price of Vigene was $323.9 million, net of $2.7 million in cash. Included in the purchase price are contingent payments fair valued at $34.5 million, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $57.5 million based on future performance). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s Manufacturing reportable segment. As of September 24, 2022, the fair value of the contingent consideration was zero as certain financial targets have not and are not expected to be achieved. Retrogenix Limited On March 30, 2021, the Company acquired Retrogenix Limited (Retrogenix), an outsourced discovery services provider specializing in bioanalytical services utilizing its proprietary cell microarray technology. The acquisition of Retrogenix enhances the Company’s scientific expertise with additional large molecule and cell therapy discovery capabilities. The purchase price of Retrogenix was $53.9 million, net of $8.5 million in cash. Included in the purchase price are contingent payments fair valued at $6.9 million, which is the maximum potential payout, and was based on a probability-weighted approach. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. Cognate BioServices, Inc. On March 29, 2021, the Company acquired Cognate BioServices, Inc. (Cognate), a cell and gene therapy CDMO offering comprehensive manufacturing solutions for cell therapies, as well as for the production of plasmid DNA and other inputs in the CDMO value chain. The acquisition of Cognate establishes the Company as a scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through cGMP production. The purchase price of Cognate was $877.9 million, net of $70.5 million in cash and includes $15.7 million of consideration for an approximate 2% ownership interest not acquired, which was redeemed in April 2022 with the ultimate payout tied to performance in 2021. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility and senior notes (Senior Notes) issued in fiscal 2021. This business is reported as part of the Company’s Manufacturing reportable segment. Distributed Bio, Inc. On December 31, 2020, the Company acquired Distributed Bio, Inc. (Distributed Bio), a next-generation antibody discovery company with technologies specializing in enhancing the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates to biopharmaceutical clients. The acquisition of Distributed Bio expands the Company’s capabilities with an innovative, large-molecule discovery platform, and creates an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development. The purchase price of Distributed Bio was $97.0 million, net of $0.8 million in cash. The total consideration includes $80.8 million cash paid, settlement of $3.0 million in convertible promissory notes previously issued by the Company during prior fiscal years, and $14.1 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $21.0 million based on future performance and milestone achievements over a one-year period). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. During the nine months ended September 24, 2022, $7.0 million of contingent consideration was paid as certain operational milestones were achieved. As of September 24, 2022, other financial targets associated with the contingent consideration were not met and the fair value of the remaining contingent consideration is zero. Other Acquisition On March 3, 2021, the Company acquired certain assets from a distributor that supports the Company’s DSA reportable segment. The purchase price was $35.4 million, which includes $19.5 million in cash paid ($5.5 million of which was paid in fiscal 2020), and $15.9 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $17.5 million based on future performance over a three-year period). The fair value of the net assets acquired included $17.3 million of goodwill, $15.2 million attributed to supplier relationships (to be amortized over a 4-year period), and $3.0 million of property, plant, and equipment. The business is reported as part of the Company’s DSA reportable segment. As of September 24, 2022, the fair value of the contingent consideration was zero as certain operational targets were not achieved. Purchase price information The purchase price allocation was as follows: Explora BioLabs (1) Vigene Retrogenix Cognate Distributed Bio April 5, 2022 June 28, 2021 March 30, 2021 March 29, 2021 December 31, 2020 (in thousands) Trade receivables $ 7,679 $ 3,548 $ 2,266 $ 18,566 $ 2,722 Other current assets (excluding cash) 1,067 1,657 209 14,128 221 Property, plant and equipment 37,369 7,649 400 52,082 2,382 Operating lease right-of-use asset, net 48,613 22,507 1,385 34,349 1,586 Goodwill (2) 215,752 239,681 34,489 611,555 71,585 Definite-lived intangible assets 70,100 93,900 22,126 270,900 24,540 Other long-term assets 556 694 — 6,098 469 Deferred revenue (3,507) (4,260) (434) (20,539) (1,319) Other current liabilities (3) (15,507) (6,319) (1,141) (45,388) (1,504) Operating lease right-of-use liabilities (Long-term) (57,193) (21,220) (1,205) (31,383) (1,123) Deferred tax liabilities (18,601) (13,958) (4,174) (32,503) (2,529) Other long-term liabilities (1,807) — — — — Total purchase price allocation $ 284,521 $ 323,879 $ 53,921 $ 877,865 $ 97,030 (1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. (2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to a prior asset acquisition that is not deductible for tax purposes. (3) In connection with its acquisitions of businesses, the Company routinely records liabilities related to indirect state and local taxes for preacquisition periods when such liabilities are estimable and deemed probable. The Company may or may not be indemnified for such indirect tax liabilities under terms of the acquisitions. As these indirect tax contingencies are resolved, actual obligations, and any indemnifications, may differ from the recorded amounts and any differences are reflected in reported results in the period in which these are resolved. Specifically for Cognate, as of March 29, 2021, the Company recorded an estimated liability of $17.0 million pertaining to indirect state sales taxes. During the nine months ended September 24, 2022, the Company received a favorable ruling from the applicable state in which the indirect state sales tax liability arose and, accordingly, this liability was reduced in full, resulting in a gain recorded through selling, general and administrative expenses in the period. The definite-lived intangible assets acquired were as follows: Explora BioLabs Vigene Retrogenix Cognate Distributed Bio Definite-Lived Intangible Assets (in thousands) Client relationships $ 64,000 $ 87,500 $ 17,340 $ 257,200 $ 16,080 Other intangible assets 6,100 6,400 4,786 13,700 8,460 Total definite-lived intangible assets $ 70,100 $ 93,900 $ 22,126 $ 270,900 $ 24,540 Weighted Average Amortization Life (in years) Client relationships 13 12 13 13 9 Other intangible assets 4 2 3 2 4 Total definite-lived intangible assets 12 11 11 13 7 Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Transaction and Integration Costs Selling, general and administrative expenses $ 3,065 $ 6,343 $ 14,604 $ 29,754 Pro forma information The following selected unaudited pro forma consolidated results of operations are presented as if the Cognate and Vigene acquisitions had occurred as of the beginning of the period immediately preceding the period of acquisition, which is December 29, 2019, after giving effect to certain adjustments. For the three and nine months ended September 25, 2021, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $4.3 million and $17.6 million, additional interest expense on borrowing of none and $5.6 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments. All other acquisitions have not been included because that information is not material to the consolidated financial statements. September 25, 2021 Three Months Ended Nine Months Ended (in thousands) (unaudited) Revenue $ 895,937 $ 2,678,596 Net income attributable to common shareholders 106,288 238,775 These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisition. RMS Japan Divestiture On October 12, 2021, the Company sold its RMS Japan operations to The Jackson Laboratory for a purchase price of $70.9 million, which included $7.9 million in cash, $3.8 million pension over funding, and certain post-closing adjustments. The RMS Japan business was reported in the Company’s RMS reportable segment. The Company determined that the RMS Japan business was not optimized within the Company’s portfolio at its current scale, and that the capital could be better deployed in other long-term growth opportunities. CDMO Sweden Divestiture On October 12, 2021, the Company sold its gene therapy CDMO site in Sweden to a private investor group for a purchase price of $59.6 million, net of $0.2 million in cash and other post-closing adjustments that may impact the purchase price. Included in the purchase price are contingent payments fair valued at $15.3 million, which were estimated using a probability weighted model (the maximum contingent contractual payments are up to $25.0 million based on future performance), as well as a purchase obligation of approximately $10.0 million between the parties. As of September 24, 2022, the fair value of the contingent payments was reduced to $7.5 million as certain financial targets are not expected to be achieved. The CDMO Sweden business was acquired in March 2021 as part of the acquisition of Cognate and was reported in the Company’s Manufacturing reportable segment. The Company routinely evaluates the strategic fit and fundamental performance of our acquisitions integrated within our global infrastructure. As part of this assessment, the Company determined that this capital could be better deployed in other long-term growth opportunities. The carrying amounts of the major classes of assets and liabilities associated with the divestitures of the businesses were as follows: October 12, 2021 RMS Japan CDMO Sweden (in thousands) Assets Current assets $ 26,524 $ 8,187 Property, plant, and equipment, net 17,379 14,339 Operating lease right-of-use assets, net — 19,733 Goodwill 4,129 27,764 Intangible assets, net — 14,089 Other assets 3,695 — Total assets $ 51,727 $ 84,112 Liabilities Current liabilities $ 8,705 $ 6,386 Operating lease right-of-use liabilities — 18,221 Long-term liabilities 94 — Total liabilities $ 8,799 $ 24,607

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	9 Months Ended
	Sep. 24, 2022
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregation of Revenue The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 88,174 $ 65,805 $ 243,901 $ 197,035 Services and products transferred at a point in time 91,940 105,453 299,165 327,827 Total RMS revenue 180,114 171,258 543,066 524,862 DSA Services and products transferred over time 618,270 531,637 1,749,977 1,571,895 Services and products transferred at a point in time 1,193 186 5,662 1,200 Total DSA revenue 619,463 531,823 1,755,639 1,573,095 Manufacturing Services and products transferred over time 89,173 93,473 276,993 240,015 Services and products transferred at a point in time 100,407 99,383 300,519 297,138 Total Manufacturing revenue 189,580 192,856 577,512 537,153 Total revenue $ 989,157 $ 895,937 $ 2,876,217 $ 2,635,110 RMS The RMS business generates revenue through the commercial production and sale of research models, research and GMP-compliant cells (cell supply), and the provision of services related to the maintenance and monitoring of research models and management of clients’ research operations. Revenue from the sale of research models and cell supply is recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the shipping terms of a contract. Revenue generated from research models services is recognized over time and is typically based on a right-to-invoice measure of progress (output method) as invoiced amounts correspond directly to the value of the Company’s performance to date. DSA The DSA business provides a full suite of integrated drug discovery services directed at the identification, screening and selection of a lead compound for drug development and offers a full range of safety assessment services including bioanalysis, drug metabolism, pharmacokinetics, toxicology and pathology. DSA services revenue is generally recognized over time using the cost-to-cost or right to invoice measures of progress, primarily representing fixed fee service contracts and per unit service contracts, respectively. Manufacturing The Manufacturing business includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO); and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Species identification service revenue is generally recognized at a point in time as identifications are completed by the Company. Biologics service revenue is generally recognized over time using the cost-to-cost measure of progress. Microbial Solutions and Avian product sales are generally recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Transaction Price Allocated to Future Performance Obligations The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of September 24, 2022. Excluded from the disclosure is the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less (ii) contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed and (iii) service revenue recognized in accordance with ASC 842, “Leases” (see additional disclosure for Other Performance Obligations). The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of September 24, 2022: Revenue Expected to be Recognized in Future Periods Less than 1 Year 1 to 3 Years 4 to 5 Years Beyond 5 Years Total (in thousands) DSA $ 609,960 $ 461,386 $ 72,772 $ 4,130 $ 1,148,248 Manufacturing 113 8 — — 121 Total $ 610,073 $ 461,394 $ 72,772 $ 4,130 $ 1,148,369 Contract Balances from Contracts with Customers The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the unaudited condensed consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: September 24, 2022 December 25, 2021 (in thousands) Balances from contracts with customers: Client receivables $ 580,626 $ 489,452 Contract assets (unbilled revenue) 199,977 160,609 Contract liabilities (current and long-term deferred revenue) 275,634 240,281 Contract liabilities (customer contract deposits) 76,904 59,512 When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $52 million and $36 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying unaudited condensed consolidated balance sheets as of September 24, 2022 and December 25, 2021, respectively. Advanced client payments of approximately $77 million and $60 million have been presented as customer contract deposits within other current liabilities in the accompanying unaudited condensed consolidated balance sheets as of September 24, 2022 and December 25, 2021, respectively. Other changes in the contract asset and the contract liability balances during the nine months ended September 24, 2022 and September 25, 2021 were as follows: (i) Changes due to acquisitions and divestitures: See Note 2 “Acquisitions and Divestitures” for the Company’s recent acquisitions. (ii) Cumulative catch-up adjustments to revenue that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration is constrained), or a contract modification: During the nine months ended September 24, 2022 and September 25, 2021, immaterial cumulative catch-up adjustments to revenue were recorded. (iii) A change in the time frame for a right to consideration to become unconditional (that is, for a contract asset to be recorded as a client receivable): Approximately 85% of unbilled revenue as of December 25, 2021, which was $161 million, was billed during the nine months ended September 24, 2022. Approximately 85% of unbilled revenue as of December 26, 2020, which was $135 million, was billed during the nine months ended September 25, 2021. (iv) A change in the time frame for a performance obligation to be satisfied (that is, for the recognition of revenue arising from a contract liability): Approximately 85% of contract liabilities as of December 25, 2021, which was $240 million, were recognized as revenue during the nine months ended September 24, 2022. Approximately 85% of contract liabilities as of December 26, 2020, which was $227 million, were recognized as revenue during the nine months ended September 25, 2021. Other Performance Obligation s As part of the Company’s service offerings, primarily in the Manufacturing and RMS segments, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. For the three months ended September 24, 2022 and September 25, 2021, the Company recognized lease revenue of $15.8 million and $5.3 million, which is recorded within service revenue, which is transferred over time, within the unaudited condensed consolidated statements of income. For the nine months ended September 24, 2022 and September 25, 2021, the Company recognized lease revenue of $37.6 million and $11.6 million within the unaudited condensed consolidated statements of income. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the unaudited condensed consolidated financial statements.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 24, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The following table presents revenue and other financial information by reportable segment: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) RMS Revenue $ 180,114 $ 171,258 $ 543,066 $ 524,862 Operating income 35,891 39,111 123,299 126,626 Depreciation and amortization 13,128 9,927 35,825 29,450 Capital expenditures 10,743 18,026 33,239 29,521 DSA Revenue $ 619,463 $ 531,823 $ 1,755,639 $ 1,573,095 Operating income 142,143 116,548 375,922 312,011 Depreciation and amortization 43,913 44,072 135,328 132,268 Capital expenditures 43,400 23,270 133,908 60,783 Manufacturing Revenue $ 189,580 $ 192,856 $ 577,512 $ 537,153 Operating income 31,479 48,563 140,350 154,717 Depreciation and amortization 17,005 13,953 53,487 34,474 Capital expenditures 18,137 13,296 65,396 34,008 The following tables present reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts: Operating Income Depreciation and Amortization Capital Expenditures September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Three Months Ended: Total reportable segments $ 209,513 $ 204,222 $ 74,046 $ 67,952 $ 72,280 $ 54,592 Unallocated corporate (58,537) (48,420) 559 734 113 944 Total consolidated $ 150,976 $ 155,802 $ 74,605 $ 68,686 $ 72,393 $ 55,536 Nine Months Ended Total reportable segments $ 639,571 $ 593,354 $ 224,640 $ 196,192 $ 232,543 $ 124,312 Unallocated corporate (152,406) (176,299) 1,685 2,107 3,166 5,685 Total consolidated $ 487,165 $ 417,055 $ 226,325 $ 198,299 $ 235,709 $ 129,997 Revenue for each significant product or service offering is as follows: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) RMS $ 180,114 $ 171,258 $ 543,066 $ 524,862 DSA 619,463 531,823 1,755,639 1,573,095 Manufacturing 189,580 192,856 577,512 537,153 Total revenue $ 989,157 $ 895,937 $ 2,876,217 $ 2,635,110 A summary of unallocated corporate expense consists of the following: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Stock-based compensation $ 13,381 $ 13,258 $ 30,415 $ 31,317 Compensation, benefits, and other employee-related expenses 28,313 17,249 77,456 70,535 External consulting and other service expenses 4,144 6,670 13,190 20,327 Information technology 4,359 4,074 9,912 12,286 Depreciation 559 734 1,685 2,107 Acquisition and integration 1,059 3,392 9,899 28,988 Other general unallocated corporate 6,722 3,043 9,849 10,739 Total unallocated corporate expense $ 58,537 $ 48,420 $ 152,406 $ 176,299 Other general unallocated corporate expense consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations. Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: September 24, 2022 $ 595,265 $ 245,928 $ 101,601 $ 43,803 $ 2,560 $ 989,157 September 25, 2021 493,564 258,353 85,252 56,607 2,161 895,937 Nine Months Ended: September 24, 2022 $ 1,688,731 $ 760,599 $ 280,541 $ 138,988 $ 7,358 $ 2,876,217 September 25, 2021 1,433,665 771,594 252,924 171,186 5,741 2,635,110 Included in the Other category above are operations located in Brazil and Israel. Revenue represents sales originating in entities physically located in the identified geographic area.

SUPPLEMENTAL BALANCE SHEET INFO

SUPPLEMENTAL BALANCE SHEET INFORMATION	9 Months Ended
	Sep. 24, 2022
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	SUPPLEMENTAL BALANCE SHEET INFORMATION The composition of trade receivables and contract assets, net is as follows: September 24, 2022 December 25, 2021 (in thousands) Client receivables $ 580,626 $ 489,452 Unbilled revenue 199,977 160,609 Total 780,603 650,061 Less: Allowance for credit losses (9,827) (7,180) Trade receivables and contract assets, net $ 770,776 $ 642,881 The composition of inventories is as follows: September 24, 2022 December 25, 2021 (in thousands) Raw materials and supplies $ 35,597 $ 33,118 Work in process 41,357 40,268 Finished products 184,568 125,760 Inventories $ 261,522 $ 199,146 The composition of other current assets is as follows: September 24, 2022 December 25, 2021 (in thousands) Prepaid income tax $ 87,038 $ 84,725 Short-term investments 950 1,063 Restricted cash 1,376 4,023 Other receivables 7,723 7,500 Other current assets $ 97,087 $ 97,311 The composition of other assets is as follows: September 24, 2022 December 25, 2021 (in thousands) Venture capital investments $ 131,515 $ 149,640 Strategic equity investments 158,582 51,712 Life insurance policies 39,938 51,048 Long-term pension assets 33,491 39,582 Other long-term income tax assets 15,088 18,690 Restricted cash 1,100 1,077 Other 49,979 41,140 Other assets $ 429,693 $ 352,889 The composition of other current liabilities is as follows: September 24, 2022 December 25, 2021 (in thousands) Current portion of operating lease right-of-use liabilities $ 44,613 $ 33,267 Customer contract deposits 76,904 59,512 Accrued income taxes 47,036 26,161 Other 13,341 18,701 Other current liabilities $ 181,894 $ 137,641 The composition of other long-term liabilities is as follows: September 24, 2022 December 25, 2021 (in thousands) Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plans $ 100,552 $ 104,944 U.S. Transition Tax 32,324 43,057 Long-term deferred revenue 24,161 20,578 Other 37,673 74,280 Other long-term liabilities $ 194,710 $ 242,859

VENTURE CAPITAL AND STRATEGIC E

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	9 Months Ended
	Sep. 24, 2022
Equity Method Investments and Joint Ventures [Abstract]
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Venture capital investments were $131.5 million and $149.6 million as of September 24, 2022 and December 25, 2021, respectively. The Company’s total commitment to the venture capital funds as of September 24, 2022 was $190.3 million, of which the Company funded $125.1 million through that date. The Company received distributions totaling $3.7 million and $10.2 million for the three months ended September 24, 2022 and September 25, 2021, respectively. The Company received distributions totaling $7.7 million and $37.7 million for the nine months ended September 24, 2022 and September 25, 2021, respectively. The Company recognized net gains on venture capital investments of $3.0 million and net losses of $10.3 million for the three months ended September 24, 2022 and September 25, 2021, respectively, both of which were driven primarily by publicly-held investments. The Company recognized net losses on venture capital investments of $20.1 million for the nine months ended September 24, 2022, driven by the decrease in the fair value of publicly-held investments offset by increases from private investments, and net losses of $15.6 million for the nine months ended September 25, 2021, which were driven by publicly-held and private investments. The Company also invests, with minority positions, directly in equity of privately-held companies. Strategic equity investments were $158.6 million and $51.7 million as of September 24, 2022 and December 25, 2021, respectively. In April 2022, the Company acquired a 49% equity interest in a supplier supporting the DSA reportable segment (the Investee) for $90.0 million up front and an additional future contingent payment of up to $5.0 million based upon the Investee’s future performance. The total allocable basis of the investment exceeds the proportional interest in the Investee’s underlying net assets by $86.7 million, which has been allocated primarily to goodwill, intangible assets (client relationships and backlog), and deferred tax liabilities in the amount of $26.2 million, $71.2 million, and $10.7 million. respectively. The Company recognizes its proportional share of the Investee’s earnings, adjusted for the amortization of the intangible assets over their useful lives and any intra-entity eliminations, under the equity method of accounting on a three-month lag within other income (expense), net in the accompanying consolidated statements of income. Summarized financial information for this equity method Investee is not presented as such information is not material to the Company’s financial statements. The Company purchased additional strategic equity investments of $33.0 million during the nine months ended September 24, 2022 and recognized insignificant gains and losses for the three and nine months ended September 24, 2022 and September 25, 2021. Additionally, in October 2022 the Company purchased an additional interest in an existing strategic equity investment for $25 million.

FAIR VALUE

FAIR VALUE	9 Months Ended
	Sep. 24, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy. Assets and liabilities measured at fair value on a recurring basis are summarized below: September 24, 2022 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 77 $ — $ 77 Other assets: Life insurance policies — 32,738 — 32,738 Total assets measured at fair value $ — $ 32,815 $ — $ 32,815 Accrued liabilities measured at fair value: Contingent consideration $ — $ — $ 8,661 $ 8,661 Total liabilities measured at fair value $ — $ — $ 8,661 $ 8,661 The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the nine months ended September 24, 2022, there were no transfers between levels. December 25, 2021 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 893 $ — $ 893 Other assets: Life insurance policies — 42,918 — 42,918 Total assets measured at fair value $ — $ 43,811 $ — $ 43,811 Accrued liabilities measured at fair value: Contingent consideration $ — $ — $ 11,794 $ 11,794 Other long-term liabilities measured at fair value: Contingent consideration — — 25,450 25,450 Total liabilities measured at fair value $ — $ — $ 37,244 $ 37,244 During the year ended December 25, 2021, there were no transfers between levels. Contingent Consideration The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Nine Months Ended September 24, 2022 September 25, 2021 (in thousands) Beginning balance $ 37,244 $ 2,328 Additions — 72,476 Payments (11,476) (2,889) Total gains or losses (realized/unrealized): Adjustment of previously recorded contingent liability (15,340) (10,360) Foreign currency translation (1,767) (226) Ending balance $ 8,661 $ 61,329 The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $53 million, of which the value accrued as of September 24, 2022 is approximately $9 million. The weighted average probability of achieving the maximum target is approximately 16%. The average volatility and weighted average cost of capital are approximately 40% and 16%, respectively. Increases or decreases in these assumptions may result in a higher or lower fair value measurement, respectively. Debt Instruments The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy. The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below: September 24, 2022 December 25, 2021 Book Value Fair Value Book Value Fair Value 4.25% Senior Notes due 2028 $ 500,000 $ 446,250 $ 500,000 $ 521,250 3.75% Senior Notes due 2029 500,000 422,500 500,000 506,700 4.0% Senior Notes due 2031 500,000 413,750 500,000 507,500 Derivative Instrument Early in November 2022, the Company entered into an interest rate swap with a notional amount of $500 million to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility, at a fixed rate of 4.700% making the total interest rate 5.825% at our current spread. The Company designated this derivative instrument as a cash flow hedge at the inception of the contract and expects it to be highly effective.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
	Sep. 24, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 25, 2021 Acquisition Related Foreign Exchange September 24, 2022 (in thousands) RMS $ 283,524 $ 215,752 $ (2,528) $ 496,748 DSA 1,472,506 — (81,136) 1,391,370 Manufacturing 955,851 (592) (67,372) 887,887 Goodwill $ 2,711,881 $ 215,160 $ (151,036) $ 2,776,005 The increase in goodwill during the nine months ended September 24, 2022 related primarily to the acquisition of Explora BioLabs in the RMS reportable segment. Intangible Assets, Net The following table displays intangible assets, net by major class: September 24, 2022 December 25, 2021 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 14,810 $ (11,800) $ 3,010 $ 12,577 $ (9,517) $ 3,060 Technology 123,169 (95,545) 27,624 135,764 (95,454) 40,310 Trademarks and trade names 12,164 (3,981) 8,184 13,086 (3,448) 9,638 Other 37,900 (18,597) 19,303 35,231 (8,445) 26,786 Other intangible assets 188,043 (129,923) 58,121 196,658 (116,864) 79,794 Client relationships 1,456,032 (546,133) 909,899 1,475,757 (494,359) 981,398 Intangible assets $ 1,644,075 $ (676,056) $ 968,020 $ 1,672,415 $ (611,223) $ 1,061,192

DEBT AND OTHER FINANCING ARRANG

DEBT AND OTHER FINANCING ARRANGEMENTS	9 Months Ended
	Sep. 24, 2022
Debt Disclosure [Abstract]
DEBT AND OTHER FINANCING ARRANGEMENTS	DEBT AND OTHER FINANCING ARRANGEMENTS Long-term debt, net and finance leases consists of the following: September 24, 2022 December 25, 2021 (in thousands) Revolving facility $ 1,429,154 $ 1,161,431 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 500,000 4.00% Senior Notes due 2031 500,000 500,000 Other debt 239 368 Finance leases 29,428 27,223 Total debt and finance leases 2,958,821 2,689,022 Less: Current portion of long-term debt — 101 Current portion of finance leases 2,079 2,694 Current portion of long-term debt and finance leases 2,079 2,795 Long-term debt and finance leases 2,956,742 2,686,227 Debt discount and debt issuance costs (19,686) (22,663) Long-term debt, net and finance leases $ 2,937,056 $ 2,663,564 As of September 24, 2022 and December 25, 2021, the weighted average interest rate on the Company’s debt was 3.85% and 2.78%, respectively. During the nine months ended September 25, 2021, the Company prepaid $500 million of Senior Notes due in 2026 along with $21 million of related debt extinguishment costs and $13 million of accrued interest using proceeds from additional senior notes issued on the same day. The payment of the 2026 Senior Notes was accounted for as a debt extinguishment. Approximately $21 million of debt extinguishment costs and $5 million of deferred financing costs write-offs were recorded in Interest expense for the nine months ended September 25, 2021. Foreign currency transactions During the three and nine months ended September 24, 2022 and September 25, 2021, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility, which were between $250 million and $400 million each. To limit this foreign currency exposure, the Company entered into foreign exchange forward contracts, which are not designated as hedging instruments. The gains and losses incurred on these transactions were as follows: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 Affected Line Item in the Consolidated Statements of Income (in thousands) Loss on foreign debt remeasurement $ (16,006) $ (4,417) $ (46,529) $ (22,680) Other expense, net Gain on foreign exchange forward contract 17,406 5,048 49,712 24,380 Interest expense Letters of Credit As of September 24, 2022 and December 25, 2021, the Company had $17.7 million in outstanding letters of credit.

EQUITY AND NONCONTROLLING INTER

EQUITY AND NONCONTROLLING INTERESTS	9 Months Ended
	Sep. 24, 2022
Equity [Abstract]
EQUITY AND NONCONTROLLING INTERESTS	EQUITY AND NONCONTROLLING INTERESTS Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Numerator: Net income $ 97,612 $ 105,159 $ 303,502 $ 259,010 Less: Net income attributable to noncontrolling interests 1,139 1,733 4,686 5,606 Net income attributable to common shareholders $ 96,473 $ 103,426 $ 298,816 $ 253,404 Denominator: Weighted-average shares outstanding - Basic 50,870 50,425 50,778 50,234 Effect of dilutive securities: Stock options, restricted stock units and performance share units 413 1,133 507 1,126 Weighted-average shares outstanding - Diluted 51,283 51,558 51,285 51,360 Anti-dilutive common stock equivalents (1) 571 154 568 158 (1) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect. Treasury Shares During the nine months ended September 24, 2022 and September 25, 2021, the Company did not repurchase any shares under its authorized stock repurchase program. As of September 24, 2022, the Company had $129.1 million remaining on the authorized stock repurchase program. The Company’s stock-based compensation plans permit the netting of common stock upon vesting of restricted stock units and performance share units in order to satisfy individual statutory tax withholding requirements. During the nine months ended September 24, 2022 and September 25, 2021, the Company acquired 0.1 million shares for $38.5 million and 0.1 million shares for $40.4 million, respectively, from such netting. Accumulated Other Comprehensive Income (Loss) Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 25, 2021 $ (98,173) $ (66,567) $ (164,740) Other comprehensive loss before reclassifications (253,181) — (253,181) Amounts reclassified from accumulated other comprehensive income — 2,218 2,218 Net current period other comprehensive (loss) income (253,181) 2,218 (250,963) Income tax (benefit) expense (20,645) 550 (20,095) September 24, 2022 $ (330,709) $ (64,899) $ (395,608) Nonredeemable Noncontrolling Interest The Company has an investment in an entity whose financial results are consolidated in the Company’s unaudited condensed consolidated financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest within Equity in the accompanying unaudited condensed consolidated balance sheets. The activity within the nonredeemable noncontrolling interest was not significant during the three and nine months ended September 24, 2022 and September 25, 2021. Redeemable Noncontrolling Interests The Company has a 92% equity interest in Vital River with an 8% redeemable noncontrolling interest. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor, which represents a derivative embedded within the equity instrument. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value ($24.2 million as of September 24, 2022) and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 8% interest, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 8% equity interest is not limited. Prior to June 2022, the Company had an 80% equity interest in a subsidiary with a 20% redeemable noncontrolling interest. In June 2022, the Company purchased an additional 10% interest in the subsidiary for $15.0 million. Beginning in 2024, the Company has the right to purchase, and the noncontrolling interest holders have the right to sell (Put/call option), the remaining 10% equity interest at its appraised value ($15.0 million as of September 24, 2022). The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the appraised value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest or a predetermined floor value. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 10% interest, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 10% equity interest is not limited. The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests: Nine Months Ended September 24, 2022 September 25, 2021 (in thousands) Beginning balance $ 53,010 $ 25,499 Purchase of a 10% redeemable noncontrolling interest (15,000) — Adjustments of noncontrolling interests to redemption values 6,681 3,043 Net income attributable to noncontrolling interests 2,963 3,674 Dividend to redeemable noncontrolling interest (3,525) — Foreign currency translation (4,923) 340 Ending balance $ 39,206 $ 32,556

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 24, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rates for the three months ended September 24, 2022 and September 25, 2021 were 20.7% and 14.7%, respectively. The Company’s effective tax rates for the nine months ended September 24, 2022 and September 25, 2021 were 19.7% and 18.3%, respectively. The increase in the three month effective tax rates from the prior year period was primarily attributable to a decreased tax benefit from stock-based compensation deductions, as well as lower research and development tax credits due to a discrete benefit in the three months ended September 25, 2021. The increase in the nine month effective tax rates is attributable primarily to the same reasons as above, partially offset with the deferred tax impact of tax law changes enacted during the nine months ended September 25, 2021. For the three months ended September 24, 2022, the Company’s unrecognized tax benefits decreased by $1.2 million to $33.3 million, primarily due to favorable foreign exchange, and the lapse of statutes of limitations, partially offset by increases in research and development tax credit reserves. For the three months ended September 24, 2022, the amount of unrecognized income tax benefits that would impact the effective tax rate decreased by $1.5 million to $29.6 million for the same reasons discussed above. The accrued interest on unrecognized tax benefits was $1.1 million as of September 24, 2022. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by approximately $10.6 million over the next twelve-month period, primarily due to audit settlements and expiring statutes of limitations. The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2018. The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, France, and India. The Company does not anticipate resolution of these audits will have a material impact on its consolidated financial statements.

RESTRUCTURING AND ASSET IMPAIRM

RESTRUCTURING AND ASSET IMPAIRMENTS	9 Months Ended
	Sep. 24, 2022
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND ASSET IMPAIRMENTS	RESTRUCTURING AND ASSET IMPAIRMENTS In recent fiscal years, the Company has undertaken productivity improvement initiatives within all reportable segments at various locations across the U.S., Canada, and Europe. This includes workforce right-sizing and scalability initiatives, resulting in severance and transition costs; and cost related to the consolidation of facilities, resulting in asset impairment and accelerated depreciation charges. The Company does not have any significant remaining lease obligations for facilities associated with restructuring activities. The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) RMS $ (110) $ — $ 1,017 $ 7 DSA 71 815 687 2,449 Manufacturing 1,165 1,516 1,543 2,385 Unallocated corporate (23) — 1,231 (151) Total $ 1,103 $ 2,331 $ 4,478 $ 4,690 As of September 24, 2022 and September 25, 2021, $1.7 million and $3.4 million, respectively, of severance and other personnel related costs liabilities and lease obligation liabilities were included in accrued compensation and accrued liabilities within the Company’s unaudited condensed consolidated balance sheets.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 24, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation Various lawsuits, claims and proceedings are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 24, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT Avian Vaccine Services Divestiture On November 1, 2022, the Company signed an agreement with a private investor group to sell its Avian Vaccine Services business (“Avian”) for approximately $170 million in cash, subject to certain customary closing adjustments, and future contingent payments up to an additional $30 million. The Company is in the process of evaluating the transaction and its impact on the consolidated financial statements. The proposed transaction is expected to close in the fourth quarter of fiscal 2022.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 24, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2021. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.
Use of Estimates	The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Newly Issued Accounting Pronouncements	In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” ASU 2022-04 requires quantitative and qualitative disclosures about the use of supplier finance programs. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for selected disclosures, and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures of the consolidated financial statements, but does not believe there will be a material impact. In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.” ASU 2022-03 sets disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU also clarifies that contractual sale restrictions should not be considered when measuring fair value of equity securities. The ASU is effective for fiscal years beginning after December 15, 2023 and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures, but does not believe there will be a material impact. In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities About Government Assistance.” ASU 2021-10 requires disclosures about transactions with a government that have been accounted for by a grant or contribution accounting model to increase transparency about the types of transactions, the accounting for the transactions, and the effect on the financial statements. The ASU is an annual disclosure effective for fiscal years beginning after December 15, 2021 and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures, but does not believe there will be a material impact.
Consolidation	The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
Fiscal Period	The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which will occur in this fiscal year 2022.
Segment Reporting	The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research and GMP-Compliant Cells businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services); and Research and GMP-Compliant Cells, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and nonregulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO); Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens.

ACQUISITIONS AND DIVESTITURES (

ACQUISITIONS AND DIVESTITURES (Tables)	9 Months Ended
	Sep. 24, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Purchase Price Allocation and Transaction and Integration Costs	The purchase price allocation was as follows: Explora BioLabs (1) Vigene Retrogenix Cognate Distributed Bio April 5, 2022 June 28, 2021 March 30, 2021 March 29, 2021 December 31, 2020 (in thousands) Trade receivables $ 7,679 $ 3,548 $ 2,266 $ 18,566 $ 2,722 Other current assets (excluding cash) 1,067 1,657 209 14,128 221 Property, plant and equipment 37,369 7,649 400 52,082 2,382 Operating lease right-of-use asset, net 48,613 22,507 1,385 34,349 1,586 Goodwill (2) 215,752 239,681 34,489 611,555 71,585 Definite-lived intangible assets 70,100 93,900 22,126 270,900 24,540 Other long-term assets 556 694 — 6,098 469 Deferred revenue (3,507) (4,260) (434) (20,539) (1,319) Other current liabilities (3) (15,507) (6,319) (1,141) (45,388) (1,504) Operating lease right-of-use liabilities (Long-term) (57,193) (21,220) (1,205) (31,383) (1,123) Deferred tax liabilities (18,601) (13,958) (4,174) (32,503) (2,529) Other long-term liabilities (1,807) — — — — Total purchase price allocation $ 284,521 $ 323,879 $ 53,921 $ 877,865 $ 97,030 (1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. (2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to a prior asset acquisition that is not deductible for tax purposes. (3) In connection with its acquisitions of businesses, the Company routinely records liabilities related to indirect state and local taxes for preacquisition periods when such liabilities are estimable and deemed probable. The Company may or may not be indemnified for such indirect tax liabilities under terms of the acquisitions. As these indirect tax contingencies are resolved, actual obligations, and any indemnifications, may differ from the recorded amounts and any differences are reflected in reported results in the period in which these are resolved. Specifically for Cognate, as of March 29, 2021, the Company recorded an estimated liability of $17.0 million pertaining to indirect state sales taxes. During the nine months ended September 24, 2022, the Company received a favorable ruling from the applicable state in which the indirect state sales tax liability arose and, accordingly, this liability was reduced in full, resulting in a gain recorded through selling, general and administrative expenses in the period.
Schedule of Definite-Lived Intangible Assets Acquired as Part of Business Combination	The definite-lived intangible assets acquired were as follows: Explora BioLabs Vigene Retrogenix Cognate Distributed Bio Definite-Lived Intangible Assets (in thousands) Client relationships $ 64,000 $ 87,500 $ 17,340 $ 257,200 $ 16,080 Other intangible assets 6,100 6,400 4,786 13,700 8,460 Total definite-lived intangible assets $ 70,100 $ 93,900 $ 22,126 $ 270,900 $ 24,540 Weighted Average Amortization Life (in years) Client relationships 13 12 13 13 9 Other intangible assets 4 2 3 2 4 Total definite-lived intangible assets 12 11 11 13 7 Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Transaction and Integration Costs Selling, general and administrative expenses $ 3,065 $ 6,343 $ 14,604 $ 29,754
Schedule of Pro Forma Information	All other acquisitions have not been included because that information is not material to the consolidated financial statements. September 25, 2021 Three Months Ended Nine Months Ended (in thousands) (unaudited) Revenue $ 895,937 $ 2,678,596 Net income attributable to common shareholders 106,288 238,775
Schedule of Major Classes of Assets and Liabilities Associated with Divestitures	The carrying amounts of the major classes of assets and liabilities associated with the divestitures of the businesses were as follows: October 12, 2021 RMS Japan CDMO Sweden (in thousands) Assets Current assets $ 26,524 $ 8,187 Property, plant, and equipment, net 17,379 14,339 Operating lease right-of-use assets, net — 19,733 Goodwill 4,129 27,764 Intangible assets, net — 14,089 Other assets 3,695 — Total assets $ 51,727 $ 84,112 Liabilities Current liabilities $ 8,705 $ 6,386 Operating lease right-of-use liabilities — 18,221 Long-term liabilities 94 — Total liabilities $ 8,799 $ 24,607

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	9 Months Ended
	Sep. 24, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 88,174 $ 65,805 $ 243,901 $ 197,035 Services and products transferred at a point in time 91,940 105,453 299,165 327,827 Total RMS revenue 180,114 171,258 543,066 524,862 DSA Services and products transferred over time 618,270 531,637 1,749,977 1,571,895 Services and products transferred at a point in time 1,193 186 5,662 1,200 Total DSA revenue 619,463 531,823 1,755,639 1,573,095 Manufacturing Services and products transferred over time 89,173 93,473 276,993 240,015 Services and products transferred at a point in time 100,407 99,383 300,519 297,138 Total Manufacturing revenue 189,580 192,856 577,512 537,153 Total revenue $ 989,157 $ 895,937 $ 2,876,217 $ 2,635,110 Revenue for each significant product or service offering is as follows: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) RMS $ 180,114 $ 171,258 $ 543,066 $ 524,862 DSA 619,463 531,823 1,755,639 1,573,095 Manufacturing 189,580 192,856 577,512 537,153 Total revenue $ 989,157 $ 895,937 $ 2,876,217 $ 2,635,110 Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: September 24, 2022 $ 595,265 $ 245,928 $ 101,601 $ 43,803 $ 2,560 $ 989,157 September 25, 2021 493,564 258,353 85,252 56,607 2,161 895,937 Nine Months Ended: September 24, 2022 $ 1,688,731 $ 760,599 $ 280,541 $ 138,988 $ 7,358 $ 2,876,217 September 25, 2021 1,433,665 771,594 252,924 171,186 5,741 2,635,110
Schedule of Estimated Revenue Related to Performance Obligations	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of September 24, 2022: Revenue Expected to be Recognized in Future Periods Less than 1 Year 1 to 3 Years 4 to 5 Years Beyond 5 Years Total (in thousands) DSA $ 609,960 $ 461,386 $ 72,772 $ 4,130 $ 1,148,248 Manufacturing 113 8 — — 121 Total $ 610,073 $ 461,394 $ 72,772 $ 4,130 $ 1,148,369
Schedule of Client Receivables, Contract Assets and Contract Liabilities	The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: September 24, 2022 December 25, 2021 (in thousands) Balances from contracts with customers: Client receivables $ 580,626 $ 489,452 Contract assets (unbilled revenue) 199,977 160,609 Contract liabilities (current and long-term deferred revenue) 275,634 240,281 Contract liabilities (customer contract deposits) 76,904 59,512

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 24, 2022
Segment Reporting [Abstract]
Schedule of Revenue and Other Financial Information by Business Segment	The following table presents revenue and other financial information by reportable segment: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) RMS Revenue $ 180,114 $ 171,258 $ 543,066 $ 524,862 Operating income 35,891 39,111 123,299 126,626 Depreciation and amortization 13,128 9,927 35,825 29,450 Capital expenditures 10,743 18,026 33,239 29,521 DSA Revenue $ 619,463 $ 531,823 $ 1,755,639 $ 1,573,095 Operating income 142,143 116,548 375,922 312,011 Depreciation and amortization 43,913 44,072 135,328 132,268 Capital expenditures 43,400 23,270 133,908 60,783 Manufacturing Revenue $ 189,580 $ 192,856 $ 577,512 $ 537,153 Operating income 31,479 48,563 140,350 154,717 Depreciation and amortization 17,005 13,953 53,487 34,474 Capital expenditures 18,137 13,296 65,396 34,008
Reconciliation of Segment Operating Income to Consolidated Operating Income	The following tables present reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts: Operating Income Depreciation and Amortization Capital Expenditures September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Three Months Ended: Total reportable segments $ 209,513 $ 204,222 $ 74,046 $ 67,952 $ 72,280 $ 54,592 Unallocated corporate (58,537) (48,420) 559 734 113 944 Total consolidated $ 150,976 $ 155,802 $ 74,605 $ 68,686 $ 72,393 $ 55,536 Nine Months Ended Total reportable segments $ 639,571 $ 593,354 $ 224,640 $ 196,192 $ 232,543 $ 124,312 Unallocated corporate (152,406) (176,299) 1,685 2,107 3,166 5,685 Total consolidated $ 487,165 $ 417,055 $ 226,325 $ 198,299 $ 235,709 $ 129,997
Revenue Disaggregated by Products and Services and Geographic Area	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 88,174 $ 65,805 $ 243,901 $ 197,035 Services and products transferred at a point in time 91,940 105,453 299,165 327,827 Total RMS revenue 180,114 171,258 543,066 524,862 DSA Services and products transferred over time 618,270 531,637 1,749,977 1,571,895 Services and products transferred at a point in time 1,193 186 5,662 1,200 Total DSA revenue 619,463 531,823 1,755,639 1,573,095 Manufacturing Services and products transferred over time 89,173 93,473 276,993 240,015 Services and products transferred at a point in time 100,407 99,383 300,519 297,138 Total Manufacturing revenue 189,580 192,856 577,512 537,153 Total revenue $ 989,157 $ 895,937 $ 2,876,217 $ 2,635,110 Revenue for each significant product or service offering is as follows: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) RMS $ 180,114 $ 171,258 $ 543,066 $ 524,862 DSA 619,463 531,823 1,755,639 1,573,095 Manufacturing 189,580 192,856 577,512 537,153 Total revenue $ 989,157 $ 895,937 $ 2,876,217 $ 2,635,110 Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: September 24, 2022 $ 595,265 $ 245,928 $ 101,601 $ 43,803 $ 2,560 $ 989,157 September 25, 2021 493,564 258,353 85,252 56,607 2,161 895,937 Nine Months Ended: September 24, 2022 $ 1,688,731 $ 760,599 $ 280,541 $ 138,988 $ 7,358 $ 2,876,217 September 25, 2021 1,433,665 771,594 252,924 171,186 5,741 2,635,110
Summary of Unallocated Corporate Overhead	A summary of unallocated corporate expense consists of the following: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Stock-based compensation $ 13,381 $ 13,258 $ 30,415 $ 31,317 Compensation, benefits, and other employee-related expenses 28,313 17,249 77,456 70,535 External consulting and other service expenses 4,144 6,670 13,190 20,327 Information technology 4,359 4,074 9,912 12,286 Depreciation 559 734 1,685 2,107 Acquisition and integration 1,059 3,392 9,899 28,988 Other general unallocated corporate 6,722 3,043 9,849 10,739 Total unallocated corporate expense $ 58,537 $ 48,420 $ 152,406 $ 176,299

SUPPLEMENTAL BALANCE SHEET IN_2

SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)	9 Months Ended
	Sep. 24, 2022
Supplemental Balance Sheet Information [Abstract]
Composition of Net Trade Receivables	The composition of trade receivables and contract assets, net is as follows: September 24, 2022 December 25, 2021 (in thousands) Client receivables $ 580,626 $ 489,452 Unbilled revenue 199,977 160,609 Total 780,603 650,061 Less: Allowance for credit losses (9,827) (7,180) Trade receivables and contract assets, net $ 770,776 $ 642,881
Composition of Inventories	The composition of inventories is as follows: September 24, 2022 December 25, 2021 (in thousands) Raw materials and supplies $ 35,597 $ 33,118 Work in process 41,357 40,268 Finished products 184,568 125,760 Inventories $ 261,522 $ 199,146
Composition of Other Current Assets	The composition of other current assets is as follows: September 24, 2022 December 25, 2021 (in thousands) Prepaid income tax $ 87,038 $ 84,725 Short-term investments 950 1,063 Restricted cash 1,376 4,023 Other receivables 7,723 7,500 Other current assets $ 97,087 $ 97,311
Composition of Other Assets	The composition of other assets is as follows: September 24, 2022 December 25, 2021 (in thousands) Venture capital investments $ 131,515 $ 149,640 Strategic equity investments 158,582 51,712 Life insurance policies 39,938 51,048 Long-term pension assets 33,491 39,582 Other long-term income tax assets 15,088 18,690 Restricted cash 1,100 1,077 Other 49,979 41,140 Other assets $ 429,693 $ 352,889
Composition of Other Current Liabilities	The composition of other current liabilities is as follows: September 24, 2022 December 25, 2021 (in thousands) Current portion of operating lease right-of-use liabilities $ 44,613 $ 33,267 Customer contract deposits 76,904 59,512 Accrued income taxes 47,036 26,161 Other 13,341 18,701 Other current liabilities $ 181,894 $ 137,641
Composition of Other Long-Term Liabilities	The composition of other long-term liabilities is as follows: September 24, 2022 December 25, 2021 (in thousands) Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plans $ 100,552 $ 104,944 U.S. Transition Tax 32,324 43,057 Long-term deferred revenue 24,161 20,578 Other 37,673 74,280 Other long-term liabilities $ 194,710 $ 242,859

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
	Sep. 24, 2022
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis are summarized below: September 24, 2022 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 77 $ — $ 77 Other assets: Life insurance policies — 32,738 — 32,738 Total assets measured at fair value $ — $ 32,815 $ — $ 32,815 Accrued liabilities measured at fair value: Contingent consideration $ — $ — $ 8,661 $ 8,661 Total liabilities measured at fair value $ — $ — $ 8,661 $ 8,661 December 25, 2021 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 893 $ — $ 893 Other assets: Life insurance policies — 42,918 — 42,918 Total assets measured at fair value $ — $ 43,811 $ — $ 43,811 Accrued liabilities measured at fair value: Contingent consideration $ — $ — $ 11,794 $ 11,794 Other long-term liabilities measured at fair value: Contingent consideration — — 25,450 25,450 Total liabilities measured at fair value $ — $ — $ 37,244 $ 37,244 September 24, 2022 December 25, 2021 Book Value Fair Value Book Value Fair Value 4.25% Senior Notes due 2028 $ 500,000 $ 446,250 $ 500,000 $ 521,250 3.75% Senior Notes due 2029 500,000 422,500 500,000 506,700 4.0% Senior Notes due 2031 500,000 413,750 500,000 507,500
Rollforward of Contingent Consideration Related to Previous Acquisitions	The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Nine Months Ended September 24, 2022 September 25, 2021 (in thousands) Beginning balance $ 37,244 $ 2,328 Additions — 72,476 Payments (11,476) (2,889) Total gains or losses (realized/unrealized): Adjustment of previously recorded contingent liability (15,340) (10,360) Foreign currency translation (1,767) (226) Ending balance $ 8,661 $ 61,329

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 24, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 25, 2021 Acquisition Related Foreign Exchange September 24, 2022 (in thousands) RMS $ 283,524 $ 215,752 $ (2,528) $ 496,748 DSA 1,472,506 — (81,136) 1,391,370 Manufacturing 955,851 (592) (67,372) 887,887 Goodwill $ 2,711,881 $ 215,160 $ (151,036) $ 2,776,005
Schedule of Intangible Assets	The following table displays intangible assets, net by major class: September 24, 2022 December 25, 2021 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 14,810 $ (11,800) $ 3,010 $ 12,577 $ (9,517) $ 3,060 Technology 123,169 (95,545) 27,624 135,764 (95,454) 40,310 Trademarks and trade names 12,164 (3,981) 8,184 13,086 (3,448) 9,638 Other 37,900 (18,597) 19,303 35,231 (8,445) 26,786 Other intangible assets 188,043 (129,923) 58,121 196,658 (116,864) 79,794 Client relationships 1,456,032 (546,133) 909,899 1,475,757 (494,359) 981,398 Intangible assets $ 1,644,075 $ (676,056) $ 968,020 $ 1,672,415 $ (611,223) $ 1,061,192

DEBT AND OTHER FINANCING ARRA_2

DEBT AND OTHER FINANCING ARRANGEMENTS (Tables)	9 Months Ended
	Sep. 24, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt and Finance Lease Obligations	Long-term debt, net and finance leases consists of the following: September 24, 2022 December 25, 2021 (in thousands) Revolving facility $ 1,429,154 $ 1,161,431 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 500,000 4.00% Senior Notes due 2031 500,000 500,000 Other debt 239 368 Finance leases 29,428 27,223 Total debt and finance leases 2,958,821 2,689,022 Less: Current portion of long-term debt — 101 Current portion of finance leases 2,079 2,694 Current portion of long-term debt and finance leases 2,079 2,795 Long-term debt and finance leases 2,956,742 2,686,227 Debt discount and debt issuance costs (19,686) (22,663) Long-term debt, net and finance leases $ 2,937,056 $ 2,663,564
Schedule of Cross Currency Loans	The gains and losses incurred on these transactions were as follows: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 Affected Line Item in the Consolidated Statements of Income (in thousands) Loss on foreign debt remeasurement $ (16,006) $ (4,417) $ (46,529) $ (22,680) Other expense, net Gain on foreign exchange forward contract 17,406 5,048 49,712 24,380 Interest expense

EQUITY AND NONCONTROLLING INT_2

EQUITY AND NONCONTROLLING INTERESTS (Tables)	9 Months Ended
	Sep. 24, 2022
Equity [Abstract]
Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) Numerator: Net income $ 97,612 $ 105,159 $ 303,502 $ 259,010 Less: Net income attributable to noncontrolling interests 1,139 1,733 4,686 5,606 Net income attributable to common shareholders $ 96,473 $ 103,426 $ 298,816 $ 253,404 Denominator: Weighted-average shares outstanding - Basic 50,870 50,425 50,778 50,234 Effect of dilutive securities: Stock options, restricted stock units and performance share units 413 1,133 507 1,126 Weighted-average shares outstanding - Diluted 51,283 51,558 51,285 51,360 Anti-dilutive common stock equivalents (1) 571 154 568 158 (1) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 25, 2021 $ (98,173) $ (66,567) $ (164,740) Other comprehensive loss before reclassifications (253,181) — (253,181) Amounts reclassified from accumulated other comprehensive income — 2,218 2,218 Net current period other comprehensive (loss) income (253,181) 2,218 (250,963) Income tax (benefit) expense (20,645) 550 (20,095) September 24, 2022 $ (330,709) $ (64,899) $ (395,608)
Rollforward Redeemable Noncontrolling Interest	The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests: Nine Months Ended September 24, 2022 September 25, 2021 (in thousands) Beginning balance $ 53,010 $ 25,499 Purchase of a 10% redeemable noncontrolling interest (15,000) — Adjustments of noncontrolling interests to redemption values 6,681 3,043 Net income attributable to noncontrolling interests 2,963 3,674 Dividend to redeemable noncontrolling interest (3,525) — Foreign currency translation (4,923) 340 Ending balance $ 39,206 $ 32,556

RESTRUCTURING AND ASSET IMPAI_2

RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)	9 Months Ended
	Sep. 24, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Costs	The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income: Three Months Ended Nine Months Ended September 24, 2022 September 25, 2021 September 24, 2022 September 25, 2021 (in thousands) RMS $ (110) $ — $ 1,017 $ 7 DSA 71 815 687 2,449 Manufacturing 1,165 1,516 1,543 2,385 Unallocated corporate (23) — 1,231 (151) Total $ 1,103 $ 2,331 $ 4,478 $ 4,690

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	9 Months Ended
	Sep. 24, 2022 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	3

ACQUISITIONS AND DIVESTITURES -

ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($) $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 05, 2022

Oct. 12, 2021

Jun. 28, 2021

Mar. 30, 2021

Mar. 29, 2021

Mar. 03, 2021

Dec. 31, 2020

Sep. 25, 2021

Sep. 24, 2022

Sep. 25, 2021

Dec. 26, 2020

Dec. 25, 2021

Business Acquisition [Line Items]

Goodwill

$ 2,776,005

$ 2,711,881

Disposal Group, Disposed of by Sale, Not Discontinued Operations | RMS Japan

Business Acquisition [Line Items]

Consideration received from divestiture

$ 70,900

Cash proceeds from divestiture

7,900

Pension over funding and other post-closing adjustments

3,800

Disposal Group, Disposed of by Sale, Not Discontinued Operations | CDMO Sweden

Business Acquisition [Line Items]

Consideration received from divestiture

59,600

Cash proceeds from divestiture

200

Contingent consideration

15,300

7,500

Disposal Group, Disposed of by Sale, Not Discontinued Operations | CDMO Sweden | Maximum

Business Acquisition [Line Items]

Contingent consideration

25,000

Purchase obligation

$ 10,000

Explora BioLabs

Business Acquisition [Line Items]

Purchase price allocation

$ 284,521

Cash acquired

6,600

Goodwill

215,752

Definite-lived intangible assets

$ 70,100

Weighted average amortization life of intangible assets acquired

12 years

Property, plant and equipment

$ 37,369

Vigene Biosciences, Inc.

Business Acquisition [Line Items]

Purchase price allocation

$ 323,879

Cash acquired

2,700

Purchase price

323,900

Contingent consideration liability

34,500

0

Goodwill

239,681

Definite-lived intangible assets

$ 93,900

Weighted average amortization life of intangible assets acquired

11 years

Property, plant and equipment

$ 7,649

Vigene Biosciences, Inc. | Maximum

Business Acquisition [Line Items]

Consideration contingent upon future performance

$ 57,500

Retrogenix Limited

Business Acquisition [Line Items]

Purchase price allocation

$ 53,921

Cash acquired

8,500

Purchase price

53,900

Contingent consideration liability

6,900

Goodwill

34,489

Definite-lived intangible assets

$ 22,126

Weighted average amortization life of intangible assets acquired

11 years

Property, plant and equipment

$ 400

Cognate BioServices, Inc.

Business Acquisition [Line Items]

Purchase price allocation

$ 877,865

Cash acquired

70,500

Purchase price

877,900

Value of consideration not acquired

$ 15,700

Ownership percentage not acquired

2%

Goodwill

$ 611,555

Definite-lived intangible assets

$ 270,900

Weighted average amortization life of intangible assets acquired

13 years

Property, plant and equipment

$ 52,082

Distributed Bio, Inc.

Business Acquisition [Line Items]

Purchase price allocation

$ 97,030

Cash acquired

800

Purchase price

97,000

Contingent consideration liability

14,100

0

Cash portion of consideration transferred

80,800

Payments to settle promissory note

3,000

Payments for contingent considerations

7,000

Goodwill

71,585

Definite-lived intangible assets

$ 24,540

Weighted average amortization life of intangible assets acquired

7 years

Property, plant and equipment

$ 2,382

Distributed Bio, Inc. | Maximum

Business Acquisition [Line Items]

Consideration contingent upon future performance

$ 21,000

Other Acquisitions

Business Acquisition [Line Items]

Purchase price

$ 35,400

Contingent consideration liability

15,900

$ 0

Cash portion of consideration transferred

19,500

$ 5,500

Goodwill

17,300

Definite-lived intangible assets

$ 15,200

Weighted average amortization life of intangible assets acquired

4 years

Property, plant and equipment

$ 3,000

Other Acquisitions | Maximum

Business Acquisition [Line Items]

Consideration contingent upon future performance

$ 17,500

Cognate BioServices, Inc. and Viegene Biosciences, Inc. | Depreciation and Amortization Expense

Business Acquisition [Line Items]

Adjustments related to prior period

$ 4,300

$ 17,600

Cognate BioServices, Inc. and Viegene Biosciences, Inc. | Interest expense

Business Acquisition [Line Items]

Adjustments related to prior period

$ 0

$ 5,600

ACQUISITIONS AND DIVESTITURES_2

ACQUISITIONS AND DIVESTITURES - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Sep. 24, 2022	Apr. 05, 2022	Dec. 25, 2021	Jun. 28, 2021	Mar. 30, 2021	Mar. 29, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 2,776,005		$ 2,711,881
Explora BioLabs
Business Acquisition [Line Items]
Trade receivables		$ 7,679
Other current assets (excluding cash)		1,067
Property, plant and equipment		37,369
Operating lease right-of-use assets, net		48,613
Goodwill		215,752
Definite-lived intangible assets		70,100
Other long-term assets		556
Deferred revenue		(3,507)
Other current liabilities		(15,507)
Operating lease right-of-use liabilities (Long-term)		(57,193)
Deferred tax liabilities		(18,601)
Other long-term liabilities		(1,807)
Total purchase price allocation		284,521
Goodwill acquired but not deductible for tax purposes		$ 5,000
Vigene
Business Acquisition [Line Items]
Trade receivables				$ 3,548
Other current assets (excluding cash)				1,657
Property, plant and equipment				7,649
Operating lease right-of-use assets, net				22,507
Goodwill				239,681
Definite-lived intangible assets				93,900
Other long-term assets				694
Deferred revenue				(4,260)
Other current liabilities				(6,319)
Operating lease right-of-use liabilities (Long-term)				(21,220)
Deferred tax liabilities				(13,958)
Other long-term liabilities				0
Total purchase price allocation				$ 323,879
Retrogenix
Business Acquisition [Line Items]
Trade receivables					$ 2,266
Other current assets (excluding cash)					209
Property, plant and equipment					400
Operating lease right-of-use assets, net					1,385
Goodwill					34,489
Definite-lived intangible assets					22,126
Other long-term assets					0
Deferred revenue					(434)
Other current liabilities					(1,141)
Operating lease right-of-use liabilities (Long-term)					(1,205)
Deferred tax liabilities					(4,174)
Other long-term liabilities					0
Total purchase price allocation					$ 53,921
Cognate
Business Acquisition [Line Items]
Trade receivables						$ 18,566
Other current assets (excluding cash)						14,128
Property, plant and equipment						52,082
Operating lease right-of-use assets, net						34,349
Goodwill						611,555
Definite-lived intangible assets						270,900
Other long-term assets						6,098
Deferred revenue						(20,539)
Other current liabilities						(45,388)
Operating lease right-of-use liabilities (Long-term)						(31,383)
Deferred tax liabilities						(32,503)
Other long-term liabilities						0
Total purchase price allocation						877,865
Estimated tax liability						$ 17,000
Distributed Bio
Business Acquisition [Line Items]
Trade receivables							$ 2,722
Other current assets (excluding cash)							221
Property, plant and equipment							2,382
Operating lease right-of-use assets, net							1,586
Goodwill							71,585
Definite-lived intangible assets							24,540
Other long-term assets							469
Deferred revenue							(1,319)
Other current liabilities							(1,504)
Operating lease right-of-use liabilities (Long-term)							(1,123)
Deferred tax liabilities							(2,529)
Other long-term liabilities							0
Total purchase price allocation							$ 97,030

ACQUISITIONS AND DIVESTITURES_3

ACQUISITIONS AND DIVESTITURES - Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 05, 2022	Jun. 28, 2021	Mar. 30, 2021	Mar. 29, 2021	Dec. 31, 2020
Explora BioLabs
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 70,100
Weighted Average Amortization Life	12 years
Vigene
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 93,900
Weighted Average Amortization Life		11 years
Retrogenix
Business Acquisition [Line Items]
Definite-Lived Intangible Assets			$ 22,126
Weighted Average Amortization Life			11 years
Cognate
Business Acquisition [Line Items]
Definite-Lived Intangible Assets				$ 270,900
Weighted Average Amortization Life				13 years
Distributed Bio
Business Acquisition [Line Items]
Definite-Lived Intangible Assets					$ 24,540
Weighted Average Amortization Life					7 years
Client relationships | Explora BioLabs
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 64,000
Weighted Average Amortization Life	13 years
Client relationships | Vigene
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 87,500
Weighted Average Amortization Life		12 years
Client relationships | Retrogenix
Business Acquisition [Line Items]
Definite-Lived Intangible Assets			$ 17,340
Weighted Average Amortization Life			13 years
Client relationships | Cognate
Business Acquisition [Line Items]
Definite-Lived Intangible Assets				$ 257,200
Weighted Average Amortization Life				13 years
Client relationships | Distributed Bio
Business Acquisition [Line Items]
Definite-Lived Intangible Assets					$ 16,080
Weighted Average Amortization Life					9 years
Other intangible assets | Explora BioLabs
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 6,100
Weighted Average Amortization Life	4 years
Other intangible assets | Vigene
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 6,400
Weighted Average Amortization Life		2 years
Other intangible assets | Retrogenix
Business Acquisition [Line Items]
Definite-Lived Intangible Assets			$ 4,786
Weighted Average Amortization Life			3 years
Other intangible assets | Cognate
Business Acquisition [Line Items]
Definite-Lived Intangible Assets				$ 13,700
Weighted Average Amortization Life				2 years
Other intangible assets | Distributed Bio
Business Acquisition [Line Items]
Definite-Lived Intangible Assets					$ 8,460
Weighted Average Amortization Life					4 years

ACQUISITIONS AND DIVESTITURES_4

ACQUISITIONS AND DIVESTITURES - Transaction and Integration Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Business Combination and Asset Acquisition [Abstract]
Selling, general and administrative expenses	$ 3,065	$ 6,343	$ 14,604	$ 29,754

ACQUISITIONS AND DIVESTITURES_5

ACQUISITIONS AND DIVESTITURES - Pro Forma Information (Details) - Cognate BioServices, Inc. and Viegene Biosciences, Inc. - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 25, 2021	Sep. 25, 2021
Business Acquisition [Line Items]
Revenue	$ 895,937	$ 2,678,596
Net income attributable to common shareholders	$ 106,288	$ 238,775

ACQUISITIONS AND DIVESTITURES_6

ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations $ in Thousands	Oct. 12, 2021 USD ($)
RMS Japan
Assets
Current assets	$ 26,524
Property, plant, and equipment, net	17,379
Operating lease right-of-use assets, net	0
Goodwill	4,129
Intangible assets, net	0
Other assets	3,695
Total assets	51,727
Liabilities
Current liabilities	8,705
Operating lease right-of-use liabilities	0
Long-term liabilities	94
Total liabilities	8,799
CDMO Sweden
Assets
Current assets	8,187
Property, plant, and equipment, net	14,339
Operating lease right-of-use assets, net	19,733
Goodwill	27,764
Intangible assets, net	14,089
Other assets	0
Total assets	84,112
Liabilities
Current liabilities	6,386
Operating lease right-of-use liabilities	18,221
Long-term liabilities	0
Total liabilities	$ 24,607

REVENUE FROM CONTRACTS WITH C_3

REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 989,157	$ 895,937	$ 2,876,217	$ 2,635,110
RMS
Disaggregation of Revenue [Line Items]
Total revenue	180,114	171,258	543,066	524,862
RMS | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	88,174	65,805	243,901	197,035
RMS | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	91,940	105,453	299,165	327,827
DSA
Disaggregation of Revenue [Line Items]
Total revenue	619,463	531,823	1,755,639	1,573,095
DSA | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	618,270	531,637	1,749,977	1,571,895
DSA | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	1,193	186	5,662	1,200
Manufacturing
Disaggregation of Revenue [Line Items]
Total revenue	189,580	192,856	577,512	537,153
Manufacturing | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	89,173	93,473	276,993	240,015
Manufacturing | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	$ 100,407	$ 99,383	$ 300,519	$ 297,138

REVENUE FROM CONTRACTS WITH C_4

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Estimated Revenue Related to Performance Obligations (Details) $ in Thousands	Sep. 24, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 1,148,369
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-09-25
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 610,073
Performance obligations expected to be satisfied, expected timing	3 months 18 days
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 461,394
Performance obligations expected to be satisfied, expected timing	2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 72,772
Performance obligations expected to be satisfied, expected timing	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 4,130
Performance obligations expected to be satisfied, expected timing	1 year
DSA
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 1,148,248
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-09-25
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	609,960
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	461,386
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	72,772
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	4,130
Manufacturing
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	121
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-09-25
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	113
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	8
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	0
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 0

REVENUE FROM CONTRACTS WITH C_5

REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Revenue from Contract with Customer [Abstract]
Payment terms			30 days
Unpaid advanced client billings	$ 52,000		$ 52,000		$ 36,000
Contract liabilities (customer contract deposits)	76,904		$ 76,904		$ 59,512
Percentage of unbilled revenue billed during period			85%	85%
Amount of unbilled revenue billed during period			$ 161,000	$ 135,000
Percentage of contract liabilities recognized as revenue during period			85%	85%
Amount of contract liabilities recognized as revenue			$ 240,000	$ 227,000
Lease revenue	$ 15,800	$ 5,300	$ 37,600	$ 11,600

REVENUE FROM CONTRACTS WITH C_6

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
Revenue from Contract with Customer [Abstract]
Client receivables	$ 580,626	$ 489,452
Contract assets (unbilled revenue)	199,977	160,609
Contract liabilities (current and long-term deferred revenue)	275,634	240,281
Contract liabilities (customer contract deposits)	$ 76,904	$ 59,512

SEGMENT INFORMATION - Revenue a

SEGMENT INFORMATION - Revenue and Other Financial Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Segment Reporting Information [Line Items]
Revenue	$ 989,157	$ 895,937	$ 2,876,217	$ 2,635,110
Operating income	150,976	155,802	487,165	417,055
Depreciation and amortization	74,605	68,686	226,325	198,299
Capital expenditures	72,393	55,536	235,709	129,997
RMS
Segment Reporting Information [Line Items]
Revenue	180,114	171,258	543,066	524,862
Operating income	35,891	39,111	123,299	126,626
Depreciation and amortization	13,128	9,927	35,825	29,450
Capital expenditures	10,743	18,026	33,239	29,521
DSA
Segment Reporting Information [Line Items]
Revenue	619,463	531,823	1,755,639	1,573,095
Operating income	142,143	116,548	375,922	312,011
Depreciation and amortization	43,913	44,072	135,328	132,268
Capital expenditures	43,400	23,270	133,908	60,783
Manufacturing
Segment Reporting Information [Line Items]
Revenue	189,580	192,856	577,512	537,153
Operating income	31,479	48,563	140,350	154,717
Depreciation and amortization	17,005	13,953	53,487	34,474
Capital expenditures	$ 18,137	$ 13,296	$ 65,396	$ 34,008

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Segment Operating Income, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Segment Reporting Information [Line Items]
Operating income	$ 150,976	$ 155,802	$ 487,165	$ 417,055
Depreciation and amortization	74,605	68,686	226,325	198,299
Capital expenditures	72,393	55,536	235,709	129,997
Total reportable segments
Segment Reporting Information [Line Items]
Operating income	209,513	204,222	639,571	593,354
Depreciation and amortization	74,046	67,952	224,640	196,192
Capital expenditures	72,280	54,592	232,543	124,312
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(58,537)	(48,420)	(152,406)	(176,299)
Depreciation and amortization	559	734	1,685	2,107
Capital expenditures	$ 113	$ 944	$ 3,166	$ 5,685

SEGMENT INFORMATION - Revenue P

SEGMENT INFORMATION - Revenue Per Significant Product or Service (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Segment Reporting Information [Line Items]
Total revenue	$ 989,157	$ 895,937	$ 2,876,217	$ 2,635,110
RMS
Segment Reporting Information [Line Items]
Total revenue	180,114	171,258	543,066	524,862
DSA
Segment Reporting Information [Line Items]
Total revenue	619,463	531,823	1,755,639	1,573,095
Manufacturing
Segment Reporting Information [Line Items]
Total revenue	$ 189,580	$ 192,856	$ 577,512	$ 537,153

SEGMENT INFORMATION - Summary o

SEGMENT INFORMATION - Summary of Unallocated Corporate Overhead (Details) - Unallocated corporate - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Segment Reporting Information [Line Items]
Stock-based compensation	$ 13,381	$ 13,258	$ 30,415	$ 31,317
Compensation, benefits, and other employee-related expenses	28,313	17,249	77,456	70,535
External consulting and other service expenses	4,144	6,670	13,190	20,327
Information technology	4,359	4,074	9,912	12,286
Depreciation	559	734	1,685	2,107
Acquisition and integration	1,059	3,392	9,899	28,988
Other general unallocated corporate	6,722	3,043	9,849	10,739
Total unallocated corporate expense	$ 58,537	$ 48,420	$ 152,406	$ 176,299

SEGMENT INFORMATION - Disaggreg

SEGMENT INFORMATION - Disaggregation of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 989,157	$ 895,937	$ 2,876,217	$ 2,635,110
U.S.
Disaggregation of Revenue [Line Items]
Total revenue	595,265	493,564	1,688,731	1,433,665
Europe
Disaggregation of Revenue [Line Items]
Total revenue	245,928	258,353	760,599	771,594
Canada
Disaggregation of Revenue [Line Items]
Total revenue	101,601	85,252	280,541	252,924
Asia Pacific
Disaggregation of Revenue [Line Items]
Total revenue	43,803	56,607	138,988	171,186
Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 2,560	$ 2,161	$ 7,358	$ 5,741

SUPPLEMENTAL BALANCE SHEET IN_3

SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
Composition of trade receivables
Client receivables	$ 580,626	$ 489,452
Unbilled revenue	199,977	160,609
Total	780,603	650,061
Less: Allowance for credit losses	(9,827)	(7,180)
Trade receivables and contract assets, net	770,776	642,881
Composition of inventories
Raw materials and supplies	35,597	33,118
Work in process	41,357	40,268
Finished products	184,568	125,760
Inventories	261,522	199,146
Composition of other current assets
Prepaid income tax	87,038	84,725
Short-term investments	950	1,063
Restricted cash	1,376	4,023
Other receivables	7,723	7,500
Other current assets	97,087	97,311
Composition of other assets
Venture capital investments	131,515	149,640
Strategic equity investments	158,582	51,712
Life insurance policies	39,938	51,048
Long-term pension assets	33,491	39,582
Other long-term income tax assets	15,088	18,690
Restricted cash	1,100	1,077
Other	49,979	41,140
Other assets	429,693	352,889
Composition of other current liabilities
Current portion of operating lease right-of-use liabilities	44,613	33,267
Customer contract deposits	76,904	59,512
Accrued income taxes	47,036	26,161
Other	13,341	18,701
Other current liabilities	181,894	137,641
Composition of other long-term liabilities
Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plans	100,552	104,944
U.S. Transition Tax	32,324	43,057
Long-term deferred revenue	24,161	20,578
Other	37,673	74,280
Other long-term liabilities	$ 194,710	$ 242,859

VENTURE CAPITAL AND STRATEGIC_2

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2022	Apr. 30, 2022	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Schedule of Equity Method Investments [Line Items]
Venture capital investments			$ 131,515		$ 131,515		$ 149,640
Committed contribution			190,300		190,300
Amount funded for venture capital investments			125,100		125,100
Distributions received			3,700	$ 10,200	7,700	$ 37,700
Gains (losses) recognized related to venture capital investments			3,000	$ (10,300)	(20,100)	$ (15,600)
Strategic equity investments			158,582		158,582		$ 51,712
Payments to acquire strategic investments					33,000
Subsequent Event
Schedule of Equity Method Investments [Line Items]
Payments to acquire strategic investments	$ 25,000
DSA Supplier
Schedule of Equity Method Investments [Line Items]
Ownership percentage		49%
Purchases of additional equity interests, net		$ 90,000
Contingent payments		$ 5,000
Allocable basis of investment in excess of proportional interest in underlying net assets			86,700		86,700
DSA Supplier | Deferred Tax Liability
Schedule of Equity Method Investments [Line Items]
Allocable basis of investment in excess of proportional interest in underlying net assets			10,700		10,700
DSA Supplier | Goodwill
Schedule of Equity Method Investments [Line Items]
Allocable basis of investment in excess of proportional interest in underlying net assets			26,200		26,200
DSA Supplier | Intangible Assets
Schedule of Equity Method Investments [Line Items]
Allocable basis of investment in excess of proportional interest in underlying net assets			$ 71,200		$ 71,200

FAIR VALUE - Fair Value of Asse

FAIR VALUE - Fair Value of Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
Current assets measured at fair value:
Cash equivalents	$ 77	$ 893
Other assets:
Life insurance policies	32,738	42,918
Total assets measured at fair value	32,815	43,811
Accrued liabilities measured at fair value:
Contingent consideration	8,661	11,794
Other long-term liabilities measured at fair value:
Contingent consideration		25,450
Total liabilities measured at fair value	8,661	37,244
Level 1
Current assets measured at fair value:
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Accrued liabilities measured at fair value:
Contingent consideration	0	0
Other long-term liabilities measured at fair value:
Contingent consideration		0
Total liabilities measured at fair value	0	0
Level 2
Current assets measured at fair value:
Cash equivalents	77	893
Other assets:
Life insurance policies	32,738	42,918
Total assets measured at fair value	32,815	43,811
Accrued liabilities measured at fair value:
Contingent consideration	0	0
Other long-term liabilities measured at fair value:
Contingent consideration		0
Total liabilities measured at fair value	0	0
Level 3
Current assets measured at fair value:
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Accrued liabilities measured at fair value:
Contingent consideration	8,661	11,794
Other long-term liabilities measured at fair value:
Contingent consideration		25,450
Total liabilities measured at fair value	$ 8,661	$ 37,244

FAIR VALUE - Contingent Conside

FAIR VALUE - Contingent Consideration (Details) - Contingent Consideration - Level 3 - USD ($) $ in Thousands	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 37,244	$ 2,328
Additions	0	72,476
Payments	(11,476)	(2,889)
Adjustment of previously recorded contingent liability	(15,340)	(10,360)
Foreign currency translation	(1,767)	(226)
Ending balance	$ 8,661	$ 61,329

FAIR VALUE - Narrative (Details

FAIR VALUE - Narrative (Details) - USD ($) $ in Thousands	Nov. 02, 2022	Sep. 24, 2022	Dec. 25, 2021	Sep. 25, 2021	Dec. 26, 2020
Subsequent Event | Revolving Facility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, fixed interest rate	4.70%
Stated interest rate	5.825%
Subsequent Event | Designated as Hedging Instrument | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amount	$ 500,000
Level 3 | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration		$ 8,661	$ 37,244	$ 61,329	$ 2,328
Weighted average probability percentage of achieving maximum target		16%
Level 3 | Average Volatility | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input		0.40
Level 3 | Weighted Average Cost of Capital | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input		0.16
Level 3 | Maximum | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration		$ 53,000

FAIR VALUE - Schedule of Fair V

FAIR VALUE - Schedule of Fair Value of Debt (Details) - Senior Notes - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate	4.25%	4.25%
4.25% Senior Notes due 2028 | Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
4.25% Senior Notes due 2028 | Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 446,250	$ 521,250
3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.75%	3.75%
3.75% Senior Notes due 2029 | Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
3.75% Senior Notes due 2029 | Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 422,500	$ 506,700
4.00% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate	4%	4%
4.00% Senior Notes due 2031 | Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
4.00% Senior Notes due 2031 | Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 413,750	$ 507,500

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Rollforward of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 24, 2022 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 2,711,881
Acquisition Related	215,160
Foreign Exchange	(151,036)
Ending balance	2,776,005
RMS
Goodwill [Roll Forward]
Beginning balance	283,524
Acquisition Related	215,752
Foreign Exchange	(2,528)
Ending balance	496,748
DSA
Goodwill [Roll Forward]
Beginning balance	1,472,506
Acquisition Related	0
Foreign Exchange	(81,136)
Ending balance	1,391,370
Manufacturing
Goodwill [Roll Forward]
Beginning balance	955,851
Acquisition Related	(592)
Foreign Exchange	(67,372)
Ending balance	$ 887,887

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
Other intangible assets
Gross	$ 1,644,075	$ 1,672,415
Accumulated Amortization	(676,056)	(611,223)
Net	968,020	1,061,192
Backlog
Other intangible assets
Gross	14,810	12,577
Accumulated Amortization	(11,800)	(9,517)
Net	3,010	3,060
Technology
Other intangible assets
Gross	123,169	135,764
Accumulated Amortization	(95,545)	(95,454)
Net	27,624	40,310
Trademarks and trade names
Other intangible assets
Gross	12,164	13,086
Accumulated Amortization	(3,981)	(3,448)
Net	8,184	9,638
Other
Other intangible assets
Gross	37,900	35,231
Accumulated Amortization	(18,597)	(8,445)
Net	19,303	26,786
Other intangible assets
Other intangible assets
Gross	188,043	196,658
Accumulated Amortization	(129,923)	(116,864)
Net	58,121	79,794
Client relationships
Other intangible assets
Gross	1,456,032	1,475,757
Accumulated Amortization	(546,133)	(494,359)
Net	$ 909,899	$ 981,398

DEBT AND OTHER FINANCING ARRA_3

DEBT AND OTHER FINANCING ARRANGEMENTS - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 24, 2022	Dec. 25, 2021
Debt Instrument [Line Items]
Finance leases	$ 29,428	$ 27,223
Total debt and finance leases	2,958,821	2,689,022
Current portion of long-term debt	0	101
Current portion of finance leases	2,079	2,694
Current portion of long-term debt and finance leases	2,079	2,795
Long-term debt and finance leases	2,956,742	2,686,227
Debt discount and debt issuance costs	(19,686)	(22,663)
Long-term debt, net and finance leases	2,937,056	2,663,564
Revolving Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,429,154	$ 1,161,431
Senior Notes | 4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate	4.25%	4.25%
Long-term debt, gross	$ 500,000	$ 500,000
Senior Notes | 3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.75%	3.75%
Long-term debt, gross	$ 500,000	$ 500,000
Senior Notes | 4.00% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate	4%	4%
Long-term debt, gross	$ 500,000	$ 500,000
Other Debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 239	$ 368

DEBT AND OTHER FINANCING ARRA_4

DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Debt Instrument [Line Items]
Weighted average interest rate	3.85%		2.78%
Loss on debt extinguishment and amortization of other financing costs	$ 3,054	$ 28,972
Deferred financing costs expensed	0	38,253
Foreign Exchange Forward | Minimum
Debt Instrument [Line Items]
Notional amount	250,000	250,000
Foreign Exchange Forward | Maximum
Debt Instrument [Line Items]
Notional amount	400,000	400,000
Senior Notes Due 2026 | Senior Notes
Debt Instrument [Line Items]
Prepayments of long-term debt		500,000
Loss on debt extinguishment and amortization of other financing costs		21,000
Payments for accrued interest		13,000
Deferred financing costs expensed		$ 5,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding	$ 17,700		$ 17,700

DEBT AND OTHER FINANCING ARRA_5

DEBT AND OTHER FINANCING ARRANGEMENTS - Cross Currency Loans (Details) - Foreign Exchange Forward - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Other expense, net
Derivatives, Fair Value [Line Items]
Gains recognized in interest expense	$ (16,006)	$ (4,417)	$ (46,529)	$ (22,680)
Interest expense
Derivatives, Fair Value [Line Items]
Gains recognized in interest expense	$ 17,406	$ 5,048	$ 49,712	$ 24,380

EQUITY AND NONCONTROLLING INT_3

EQUITY AND NONCONTROLLING INTERESTS - Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Numerator:
Net income	$ 97,612	$ 105,159	$ 303,502	$ 259,010
Less: Net income attributable to noncontrolling interests	1,139	1,733	4,686	5,606
Net income attributable to common shareholders	$ 96,473	$ 103,426	$ 298,816	$ 253,404
Denominator:
Weighted-average shares outstanding—Basic (in shares)	50,870	50,425	50,778	50,234
Effect of dilutive securities:
Stock options, restricted stock units and performance share units (in shares)	413	1,133	507	1,126
Weighted-average shares outstanding—Diluted (in shares)	51,283	51,558	51,285	51,360
Anti-dilutive common stock equivalents (in shares)	571	154	568	158

EQUITY AND NONCONTROLLING INT_4

EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	9 Months Ended
	Jun. 25, 2022	Sep. 24, 2022	Sep. 25, 2021	May 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)		0.1	0.1
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments		$ 38,500	$ 40,400
Redeemable noncontrolling interests		39,206	$ 32,556		$ 53,010	$ 25,499
Vital River
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contractually defined redemption value		24,200
Supplier
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Redeemable noncontrolling interests		$ 15,000
Vital River
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest		92%
Noncontrolling interest ownership percentage		8%
Supplier
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest				80%
Noncontrolling interest ownership percentage		10%		20%
Increase in ownership percentage		10%
Purchase of additional equity interest	$ 15,000
Authorized Share Repurchase Program
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares repurchased during period (in shares)		0	0
Remaining authorized repurchase amount		$ 129,100

EQUITY AND NONCONTROLLING INT_5

EQUITY AND NONCONTROLLING INTERESTS - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	$ 2,652,927	$ 2,323,280	$ 2,538,982	$ 2,118,169
Other comprehensive loss before reclassifications			(253,181)
Amounts reclassified from accumulated other comprehensive income			2,218
Net current period other comprehensive (loss) income			(250,963)
Income tax (benefit) expense	(11,201)	(3,140)	(20,095)	(1,716)
Ending balance	2,632,738	2,432,065	2,632,738	2,432,065
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(98,173)
Other comprehensive loss before reclassifications			(253,181)
Amounts reclassified from accumulated other comprehensive income			0
Net current period other comprehensive (loss) income			(253,181)
Income tax (benefit) expense			(20,645)
Ending balance	(330,709)		(330,709)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(66,567)
Other comprehensive loss before reclassifications			0
Amounts reclassified from accumulated other comprehensive income			2,218
Net current period other comprehensive (loss) income			2,218
Income tax (benefit) expense			550
Ending balance	(64,899)		(64,899)
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(258,555)	(108,021)	(164,740)	(138,874)
Ending balance	$ (395,608)	$ (132,779)	$ (395,608)	$ (132,779)

EQUITY AND NONCONTROLLING INT_6

EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 53,010	$ 25,499
Purchase of a 10% redeemable noncontrolling interest	(15,000)	0
Adjustments of noncontrolling interests to redemption values	6,681	3,043
Net income attributable to noncontrolling interests	2,963	3,674
Dividend to redeemable noncontrolling interest	(3,525)	0
Foreign currency translation	(4,923)	340
Ending balance	$ 39,206	$ 32,556

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Income Tax Disclosure [Abstract]
Effective tax rate	20.70%	14.70%	19.70%	18.30%
Decrease in unrecognized tax benefits	$ (1.2)
Unrecognized tax benefits	33.3		$ 33.3
Increase (decrease) in unrecognized tax benefits that would impact effective tax rate	(1.5)
Unrecognized tax benefits that would impact effective tax rate	29.6		29.6
Accrued interest on unrecognized tax benefits	1.1		1.1
Decrease in unrecognized tax benefits that are reasonably possibly over the next twelve-month period	$ 10.6		$ 10.6

RESTRUCTURING AND ASSET IMPAI_3

RESTRUCTURING AND ASSET IMPAIRMENTS - Restructuring Costs by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Segment Reporting Information [Line Items]
Total	$ 1,103	$ 2,331	$ 4,478	$ 4,690
Unallocated corporate
Segment Reporting Information [Line Items]
Total	(23)	0	1,231	(151)
RMS
Segment Reporting Information [Line Items]
Total	(110)	0	1,017	7
DSA
Segment Reporting Information [Line Items]
Total	71	815	687	2,449
Manufacturing
Segment Reporting Information [Line Items]
Total	$ 1,165	$ 1,516	$ 1,543	$ 2,385

RESTRUCTURING AND ASSET IMPAI_4

RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) - USD ($) $ in Millions	Sep. 24, 2022	Sep. 25, 2021
Restructuring and Related Activities [Abstract]
Severance and other personnel related costs liability and lease obligation liabilities	$ 1.7	$ 3.4

Subsequent Event (Details)

Subsequent Event (Details) - Avian Vaccine Services - Forecast $ in Millions	3 Months Ended
	Dec. 31, 2022 USD ($)
Subsequent Event [Line Items]
Cash proceeds from divestiture	$ 170
Contingent payments upon selling business	$ 30